CM350 group2
Phase 2Biologic
CM350 group2 is one of 38 biologic programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
225 competitors in Patients With Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Halaven
EisaiPhase 2
Ensacove
XXcovery Holdings, Inc.
Phase 2
Albumin-Bound Paclitaxel
Bristol-Myers SquibbPhase 2
Carboplatin AUC-5
Merck & Co.Phase 2
HRS-4642
JJiangsu HengRui Medicine Co., Ltd.
Phase 2
AK112
SSummit Therapeutics
Phase 2
Almonertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 2
QL2107
Qilu Pharmaceutical Co., Ltd.Phase 2
RMC-6236
Revolution MedicinesPhase 2
QL1706
Qilu Pharmaceutical Co., Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CM350 group2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- KKeymed Biosciences Co.Ltd